Plasmin induces the formation of multicellular spheroids of breast cancer cells.

[1]  C. Eggers,et al.  CANCER OF THE BREAST , 1941, Annals of surgery.

[2]  R. Sutherland,et al.  Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. , 1971, Journal of the National Cancer Institute.

[3]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[4]  J. Yuhas,et al.  A simplified method for production and growth of multicellular tumor spheroids. , 1977, Cancer research.

[5]  S. O’Brien,et al.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. , 1978, Cancer research.

[6]  R. Weichselbaum,et al.  Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. , 1980, Cancer research.

[7]  R. Durand.  Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. , 1981, Cancer research.

[8]  S. Husain,et al.  Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. , 1983, Archives of biochemistry and biophysics.

[9]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[10]  N. Geller,et al.  Endotoxin‐induced in vitro release of interleukin‐1 by cancer patients' monocytes: Relation to stage of disease , 1983, International journal of cancer.

[11]  K. Robbins,et al.  A functionally active heavy chain derived from human high molecular weight urokinase. , 1983, The Journal of biological chemistry.

[12]  C. Erlichman,et al.  Cytotoxicity of adriamycin in MGH-U1 cells grown as monolayer cultures, spheroids, and xenografts in immune-deprived mice. , 1984, Cancer research.

[13]  T. Nederman.  Effects of vinblastine and 5-fluorouracil on human glioma and thyroid cancer cell monolayers and spheroids. , 1984, Cancer Research.

[14]  B. Munro.  Statistical methods for health care research , 1986 .

[15]  F. Blasi,et al.  Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.

[16]  R. Sutherland.  Cell and environment interactions in tumor microregions: the multicell spheroid model. , 1988, Science.

[17]  J. Carlsson,et al.  Extracellular matrices in multicellular spheroids of human glioma origin: Increased incorporation of proteoglycans and flbronectin as compared to monolayer cultures , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  D. Rifkin,et al.  Cell-associated plasminogen activation: regulation and physiological functions. , 1988, Annual review of cell biology.

[19]  L. Kunz,et al.  Interrelationship among morphology, metabolism, and proliferation of tumor cells in monolayer and spheroid culture. , 1989, Advances in experimental medicine and biology.

[20]  M. Scully,et al.  Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. , 1989, The Journal of biological chemistry.

[21]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[22]  B. Schwartz,et al.  Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. , 1991, The Journal of biological chemistry.

[23]  G. Leipnitz,et al.  Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. , 1991, Thrombosis research.

[24]  M L Lesser,et al.  Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[26]  V. Ellis,et al.  The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion , 1992, Annals of the New York Academy of Sciences.

[27]  F. Blasi,et al.  Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy? , 1994, Trends in pharmacological sciences.

[28]  P. Herter,et al.  Effects of nIFN β and rifn γ on growth and morphology of two human melanoma cell lines: Comparison between two‐and three‐dimensional culture , 1994 .

[29]  B. Ljung,et al.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. , 1994, Cancer research.